Therapeutic Indications

Cerliponase alfa is indicated for:

Neuronal ceroid lipofuscinosis type 2 (CLN2) disease, tripeptidyl peptidase 1 (TPP1) deficiency

Irrespective of gender only Adults (18 - 65 years old)

Cerliponase alfa is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intracisternal - 300 mg every other week

Neuronal ceroid lipofuscinosis type 2 (CLN2) disease, tripeptidyl peptidase 1 (TPP1) deficiency

Irrespective of gender only Minors (0 - 18 years old)

Cerliponase alfa is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intracisternal - 100-300 mg every other week

Contraindications

Active ingredient Cerliponase alfa is contraindicated in the following cases:

Ventriculo-peritoneal shunts

No gender/age discrimination

CLN2 patients with ventriculo-peritoneal shunts.